Navigation Links
Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder
Date:4/24/2008

sk for relapse of this devastating blood disorder."

The study showed that extremely low levels of ADAMTS13 activity are associated with increased risk of TTP relapses during remission. A key characteristic of the assay is that it is more sensitive than other assays and exhibits improved accuracy at low (<2.5 percent) ADAMTS13 activity.

"These study findings represent an important milestone, as they demonstrate that the test -- which our Company co-developed with the OSU Research Foundation -- could be utilized not only for diagnosing TTP, but also for surveillance of TTP patients during clinical remission," said Gail Page, President and CEO of Vermillion. "Vermillion is dedicated to the development and commercialization of molecular diagnostic tests to help physicians and their patients diagnose and appropriately treat diseases, particularly cardiovascular disease and cancer. The TTP test is an example of how our technology has led to significant new means to properly diagnose and screen patients with this serious disorder."

Using the SELDI-TOF technology, the TTP test could help physicians make the correct diagnosis, initiate timely treatment, and evaluate response to therapy. These new study findings suggest that the test can additionally be used to help screen for the risk of relapse in patients with TTP.

About the Study

ADAMTS13 activity and ADAMTS13 antibody (IgG) were evaluated in 157 clinical samples collected prospectively during periods of clinical remission from 24 TTP patients enrolled in other prospective studies at OSU. These patients received regular follow-up for an average of 23 months, with serial samples taken at 3-month intervals. Nine episodes of TTP relapse occurred among six patients. Logistic regression modeling was used to define the relationship between ADAMTS13 activity levels and the probability of TTP relapses.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
2. Vermillion Receives Award From the Society of Gynecologic Oncologists
3. Free Prostate Cancer Seminar in Lake Ridge, VA: Dr. Charles Snuffy Myers Announces Vitamin D Clinical Trials
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
6. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
7. SuperGens MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib
8. Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges
9. Wayne State University and Oakwood Partner in New Device to Combat Congestive Heart Failure
10. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
11. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2, 2015 Numotion,s Board of Directors and ... Tamas Feitel has joined the Company as ... a highly successful 18 year career at GE serving ... profitability, and productivity to result in significant industry leading ... Chief Financial Officer for GE Healthcare Global Services, a ...
(Date:7/2/2015)... , July 2, 2015   Decision ... European retinal specialists identify less frequent dosing as ... (DME), due to the burden on both patients ... endothelial growth factor (VEGF) injections, which are the ... Partners, abicipar pegol, which is in development for ...
(Date:7/2/2015)... , July 2, 2015 The ... & Heterofermentative), Species (Lactobacillus, Pediococcus & Enterococcus), Enzymes (Fibre-digesting ... Forecast to 2020", Silage Inoculants & Enzymes Market is ... CAGR of 4.0% from 2015 to 2020. ... igures spread through 194 P ages ...
Breaking Medicine Technology:Numotion Names Tamas Feitel Chief Financial Officer 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4
... (Nasdaq: PRGO ; TASE) announced that it ... the store brand equivalent to Schering-Plough,s Claritin-D® 12 hour ... indicated for the treatment of nasal allergy symptoms. Its ... data provided by Wolters, Kluwer. Perrigo,s ...
... ARBOR, Mich. and CAMBRIDGE, Mass., Feb. 14, 2012 ... three-year licensing agreement with H3 Biomedicine, Inc. to Compendia,s ... and Oncomine Power Tools Edition. In addition, ... from The Cancer Genome Atlas (TCGA) to discover novel ...
Cached Medicine Technology:Perrigo Announces the Launch of Loratadine-D 12 Store Brand Labels -- the First Store Brand Launch That Compares to Claritin-D® 12 2Compendia Bioscience and H3 Biomedicine Announce Strategic Collaboration to Apply Cancer Genomics to Discover and Develop Next Generation Cancer Therapeutics 2
(Date:7/3/2015)... MO (PRWEB) , ... July 03, 2015 , ... Talcum ... website to replace their existing Talcum Powder Cancer Lawsuit Center website. Just as the ... talcum powder lawsuit news , offering timely lawsuit updates and ovarian cancer warning information. ...
(Date:7/3/2015)... ... 03, 2015 , ... First Choice Emergency Room , the largest network ... as the new Medical Director of its Frisco facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:7/3/2015)... ... July 03, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The ... he says will reveal biblical truth and expose popular lies regarding proper relationships according ... Don’t Have Sex”, immediately goes into the core of the subject by explaining why ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... The Celebrity ... or cocktail dresses similar to those of celebrities will have the opportunity to get ... at checkout. This ensures that people do not have to use coupon codes or ...
(Date:7/2/2015)... ... ... pleased to announce the opening of its newest location in Dallas, Texas. The opening is ... chain was listed as #22 on the Inc. 500 list of fastest growing companies in ... located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 , “We are excited ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2
... advisory committee to the U.S. Food and Drug Administration recommended ... used without a prescription. The FDA does not have to ... does. There is no deadline for making a decision. // ... the ability to do both good and harm. Claritin, Allegra ...
... Hypertensive drugs in general have a common side effect- ... plagues people on a widely-used blood pressure medication.// ... treat high blood pressure, heart failure and other cardiac ... inhibitors are troubled by a cough. The side effect ...
... contains polyphenols in the form of flavonoids and its ... properties. Polyphenols protect the cells from damaging// physiological process ... Oxidation produces free radicals these are unstable ... increased amount of them can damage cells resulting in ...
... supplements of a fatty acid found in fish oil halves ... research has found that eating oily fish such as tuna ... caused by a particular type of irregular heartbeat. This study ... a therapy without side effects for heart patients. ...
... to a new study shows that women with ... 'good' cholesterol when they take oestrogen.// Previous research suggests ... heart disease. Now doctors at Forest University have discovered ... profile responds to HRT. ,An analysis of over ...
... An Australian psychiatrist has discovered that treating patients with ... Although antipsychotic drugs like risperidone have been shown to ... researchers have suspected for some time that oestrogen can ... version of the disease than men and it usually ...
Cached Medicine News:
BD Beaver Cataract blade, 30.0 mm long x 2.2 mm wide, designed for ICCE and ECCE procedures, designed for ICCE and ECCE, sterile....
BD Beaver DeBakey blade, 5 mm cutting width, sterile....
... standard trial frames. They are made of optical quality ... box. There are two sets available providing a full ... is that a patient can wear the prism with ... the patient to adapt to the use of the ...
Developed for reconstructive plastic surgery with E-Type coupling. Order blades by size from 12 mm, 25 mm, 50 mm or 75 mm depending on your specific case requirements. Blades come in packs of 10....
Medicine Products: